The dynamics of the cancer cachexia market is anticipated to change in the coming years owing to the positive outcomes of the some of the rare candidates during the developmental stage by key players, such as Actimed Therapeutics, Aveo Oncology, Pfizer, Incyte, Extend Biosciences, and others that are under the early phase of clinical development and have the potential to create a significant positive shift in cancer cachexia market size.
DelveInsight’s Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Cancer Cachexia Market Report
- Leading cancer cachexia companies such as Pfizer, Actimed Therapeutics, Incyte Corporation, Aveo Oncology, Extend Biosciences, AEterna Zentaris, and others are developing novel drug candidates to improve the cancer cachexia treatment landscape.
- The cancer cachexia therapies in the pipeline include PF 06946860, ACM-001, Jakafi, AV-380, EXT418, Macimorelin, and others.
- Cancer cachexia patients are typically unresponsive to standard therapeutic options, and their loss of skeletal muscle and fat differentiate it from starvation.
- There are currently no reliable biomarkers for identifying pre-cachectic patients who are likely to advance further or the rate at which they will progress to the next stage.
Discover more about therapies set to grab major cancer cachexia market share @ Cancer Cachexia Research
Cancer Cachexia Overview
Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia (lack of appetite), asthenia, and anemia. The pathogenesis of this disease is multifaceted, owing to a complicated interplay of tumor and host factors. It occurs in people with advanced cancer, chronic obstructive pulmonary disease, chronic infection (including AIDS and TB), chronic heart failure, and rheumatoid arthritis. Cancer cachexia is classified into three clinical stages: precachexia, cachexia, and refractory cachexia. Patients with cachexia who no longer respond to cancer therapy have a poor performance score and a cancer cachexia life expectancy of fewer than 3 months.
The first cancer cachexia symptoms are muscle and fat loss, which makes the person appear malnourished. While some persons appear to be of normal weight, they may exhibit symptoms such as fatigue, anemia, fat loss, and others. The immune system’s reaction to cancer and other cancer cachexia causes is being examined to understand the underlying factors behind cachexia better. Cancer cachexia diagnosis is determined using a combination of body mass index (a weight-and-height calculation), lean muscle mass, and blood testing.
Cancer Cachexia Epidemiology Segmentation
The cancer cachexia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into
- Incident/Prevalent Cases of Cancer Cachexia
- Diagnosed Cases of Cancer Cachexia
- Treatable Cases of Cancer Cachexia
Download the report to understand which factors are driving cancer cachexia epidemiology trends @ Cancer Cachexia Epidemiological Insights
Cancer Cachexia Treatment Market
Currently, potential cancer cachexia treatment options include nutritional counseling or appetite stimulants, cytokine-based therapeutic approaches, and anabolic steroids. Several pharmaceutical and dietary methods have been utilized to treat cancer cachexia. Keeping in mind that both anorexia and metabolic abnormalities are implicated, many treatment techniques have concentrated on two fundamental variables, namely, boosting appetite and neutralizing metabolic disturbances. Single therapy may not be the optimal technique for treating cachexia, and treatment regimens with many combinations are more likely to be effective. Indeed, several studies have found that combining various nutraceuticals with a high-energy diet has favorable effects.
Adlumiz (Anamorelin) from Ono Pharmaceuticals was recently approved for cancer cachexia treatment in Japan. Helsinn Healthcare is currently conducting Phase III trials in the US and other countries to assess the capability of Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC patients.
Other significant competitors in the growing therapeutic cancer cachexia market include Pfizer (PF 06946860), Actimed Therapeutics (ACM-001), Aveo Oncology (AV-380), Extend Biosciences (EXT418), and others.
To know more about cancer cachexia treatment, visit @ Cancer Cachexia Treatment Guidelines
Cancer Cachexia Pipeline Therapies and Key Companies
- PF 06946860: Pfizer
- ACM-001: Actimed Therapeutics
- Jakafi: Incyte Corporation
- AV-380: Aveo Oncology
- EXT418: Extend Biosciences
- Macimorelin: AEterna Zentaris
Learn more about the cancer cachexia therapies @ Cancer Cachexia Treatment Options
Cancer Cachexia Market Dynamics
The dynamics of the cancer cachexia market are expected to shift in the coming years as a result of the positive outcomes of some of the rare candidates during the development stage by key players that are in the early stages of clinical development have the potential to create a significant positive shift. The emerging therapies are projected to be launched during the forecast period. In addition, the dearth of effective therapies for this condition presents a great opportunity for pharma companies to create novel drugs because there is less competition in the cancer cachexia market. Moreover, the rising awareness about the condition is also impacting the growth of the cancer cachexia market positively.
However, some barriers are impeding the cancer cachexia market growth. Studies have shown that cancer patients who have cachexia respond poorly to chemotherapy, are at a greater risk of infection, and have a reduced life. At least 30% of cancer patients die from cachexia, not cancer. Mortality rates of patients with cachexia range from 0–80% in cancer cachexia. Moreover, the undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that strive for the cancer cachexia market growth.
Scope of the Cancer Cachexia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Cancer Cachexia Companies: Pfizer (NYSE: PFE), Actimed Therapeutics, Incyte Corporation (NASDAQ: INCY), Aveo Oncology (NASDAQ: AVEO), Extend Biosciences, AEterna Zentaris (NASDAQ: AEZS), and others
- Key Cancer Cachexia Therapies: PF 06946860, ACM-001, Jakafi, AV-380, EXT418, Macimorelin, and others
- Therapeutic Assessment: Cancer Cachexia current marketed and emerging therapies
- Cancer Cachexia Market Dynamics: Cancer Cachexia market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Cancer Cachexia Market Access and Reimbursement
Discover more about cancer cachexia drugs in development @ Cancer Cachexia Clinical Trials
Table of Contents
| 1. | Key Insights |
| 2. | Report Introduction |
| 3. | Cancer Cachexia Market Overview at a Glance |
| 4. | Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Management and Treatment |
| 7. | Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Emerging Therapies |
| 10. | 7MM Cancer Cachexia Market Analysis |
| 11. | Cancer Cachexia Market Outlook |
| 12. | Cancer Cachexia Market Drivers |
| 13. | Cancer Cachexia Market Barriers |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Get in touch with our Business executive @ Healthcare Due Diligence Services
Related Reports
Cancer Cachexia Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key cancer cachexia companies, including Pfizer, Actimed Therapeutics, Incyte Corporation, Aveo Oncology, Extend Biosciences, among others.
Cancer Cachexia Epidemiology Forecast
Cancer Cachexia Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted cancer cachexia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Anorexia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key anorexia companies, including Amgen, COMPASS Pathways, Benuvia Therapeutics, among others.
Cancer Anorexia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cancer anorexia companies, including Par Pharmaceutical, Helsinn Therapeutics, PRA Health Sciences, among others.
Cancer Anorexia-Cachexia Syndrome Market
Cancer Anorexia-Cachexia Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cancer anorexia-cachexia syndrome companies including Xinqiao Hospital of Chongqing, Chengdu University of Traditional Chinese Medicine, Phramongkutklao College of Medicine and Hospital, among others.
Obesity Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key obesity companies, including Novartis, Eli Lily &Company, Scohia Pharma, among others.
Other Trending Reports
Pediatric Growth Hormone Deficiency Market | Non-Cystic Fibrosis Bronchiectasis Market | X-Linked Retinitis Pigmentosa Market | Otitis Media Market | Central Retinal Vein Occlusion Market | Frontotemporal Dementia Market | Follicular Lymphoma Market | Diabetes Market | Blastic Plasmacytoid Dendritic Cell Neoplasm Market | Bevacizumab Biosimilars Insight | Bacterial Conjunctivitis Market | FENEBRUTINIB Market | Peripherally Inserted Central Catheter Devices Market | Cardiac Biomarkers Testing Devices Market
Related Healthcare Blogs
Eating Disorders Market Landscape
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
Related Healthcare Blogs
Eating Disorders Market Landscape
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187